Your browser doesn't support javascript.
loading
Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis.
Ryan, C; Menter, A; Guenther, L; Blauvelt, A; Bissonnette, R; Meeuwis, K; Sullivan, J; Cather, J C; Yosipovitch, G; Gottlieb, A B; Merola, J F; Callis Duffin, K; Fretzin, S; Osuntokun, O O; Burge, R; Naegeli, A N; Yang, F E; Lin, C-Y; Todd, K; Potts Bleakman, A.
Afiliação
  • Ryan C; Department of Dermatology, Blackrock Clinic, Dublin, Ireland.
  • Menter A; Department of Dermatology, Baylor University Medical Center, Dallas, TX, U.S.A.
  • Guenther L; Guenther Dermatology Research Centre, London, ON, Canada.
  • Blauvelt A; Oregon Medical Research Center, Portland, OR, U.S.A.
  • Bissonnette R; Innovaderm Research, Montreal, QC, Canada.
  • Meeuwis K; Department of Dermatology, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Sullivan J; Kingsway Dermatology, Miranda, NSW, Australia.
  • Cather JC; Modern Research Associates, Dallas, TX, U.S.A.
  • Yosipovitch G; Department of Dermatology and Itch Center, University of Miami School of Medicine, Miami, FL, U.S.A.
  • Gottlieb AB; Department of Dermatology, New York Medical College at Metropolitan Hospital, New York, NY, U.S.A.
  • Merola JF; Department of Dermatology and Medicine, Division of Rheumatology, Harvard Medical School Brigham and Women's Hospital, Boston, MA, U.S.A.
  • Callis Duffin K; Department of Dermatology, University of Utah School of Medicine, Salt Lake City, UT, U.S.A.
  • Fretzin S; Dawes Fretzin Dermatology Group, Indianapolis, IN, U.S.A.
  • Osuntokun OO; Eli Lilly and Company, Indianapolis, IN, U.S.A.
  • Burge R; Eli Lilly and Company, Indianapolis, IN, U.S.A.
  • Naegeli AN; Eli Lilly and Company, Indianapolis, IN, U.S.A.
  • Yang FE; Eli Lilly and Company, Indianapolis, IN, U.S.A.
  • Lin CY; Eli Lilly and Company, Indianapolis, IN, U.S.A.
  • Todd K; Eli Lilly and Company, Indianapolis, IN, U.S.A.
  • Potts Bleakman A; Eli Lilly and Company, Indianapolis, IN, U.S.A.
Br J Dermatol ; 179(4): 844-852, 2018 10.
Article em En | MEDLINE | ID: mdl-29747232
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Prurido / Psoríase / Fármacos Dermatológicos / Anticorpos Monoclonais Humanizados Idioma: En Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Irlanda
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Prurido / Psoríase / Fármacos Dermatológicos / Anticorpos Monoclonais Humanizados Idioma: En Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Irlanda